RESI Europe Moves to Portugal on March 23, 2026

19 Aug

Redefining Every Stage of Investment comes to Lisbon 

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022Life Science Nation (LSN) is excited to announce that the RESI (Redefining Every Stage of Investment) Europe Conference is moving to Lisbon, Portugal. RESI Europe will take place in person on March 23, 2026, at the EPIC SANA Lisboa Hotel (Av Eng. Duarte Pacheco, 15, 1070-100 Lisboa, Portugal), followed by two days of virtual partnering on March 24–25, 2026.

This move aligns RESI Europe with BIO-Europe Spring, bringing the value of RESI’s curated investor network and partnering platform to Europe at a pivotal time for innovators seeking global connections.

What RESI Europe Offers

RESI: Redefining Every Stage of Investment is designed to connect life science and healthcare companies with the most relevant investors and strategic partners. Each RESI conference convenes hundreds of investors actively seeking opportunities across the 4Ds:

  • Drugs/Therapeutics
  • Medical Devices
  • Diagnostics
  • Digital Health

The RESI Experience

At RESI Europe in Lisbon, attendees will benefit from all the core components that set RESI apart:

  • Partnering for One-to-One Meetings – A structured matchmaking system aligning entrepreneurs with investors and partners who fit their stage, sector, and capital needs.
  • Investor Panels – Insights from leading global investors on emerging trends, investment priorities, and expectations from early-stage companies.
  • Workshops – Practical sessions led by industry experts on fundraising, deal-making, and market entry strategies.
  • Innovator’s Pitch Challenge (IPC) – Companies pitch to a dedicated panel of investors who provide interactive feedback. IPC participants also receive partnering access, exhibit space in the RESI Exhibition Hall, and the chance to win complimentary registration for a future RESI conference.
  • Networking and the Collision Factor – Opportunities beyond formal partnering to meet new stakeholders, explore synergies, and spark collaborations.

Why Lisbon

Lisbon is a rising life science and technology hub, making it a strategic new home for RESI Europe. With BIO-Europe Spring taking place in the same city, attendees can maximize their time and connections by participating in two premier global partnering events during one trip.

Register for RESI Europe

Tags: , , , , , , ,

Impact Investors & Venture Philanthropy Panel 

19 Aug

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

As healthcare innovation continues to accelerate, the role of impact investors and venture philanthropists has become increasingly vital. These funders are not only focused on financial returns but also on advancing health equity, improving patient outcomes, and addressing pressing unmet needs across the life science ecosystem.

At RESI Boston this September, the Impact Investors & Venture Philanthropy Panel will spotlight how this unique group of investors deploys capital to drive meaningful change in healthcare. Panelists will share their perspectives on how they define and measure impact, what differentiates their investment approach from traditional venture capital, and how they partner with founders to align their mission with milestone-driven growth. Attendees will gain a deeper understanding of how these organizations catalyze innovation in areas often overlooked by mainstream funding.

This discussion will feature:

David-Fogel Jonathan-Behr Andres-Hurtado-Lorenzo
David Fogel
Member of Screening & Due Diligence Committees
Mass Medical Angels
(Moderator)		 Jonathan Behr
Partner
Dementia Discovery Fund		 Andres Hurtado-Lorenzo
SVP, Translational Research & IBD Ventures
Crohn’s and Colitis Foundation
Ron-Levin Stephanie-Oestreich
Ron Levin
Managing Partner
Alumni Ventures		 Stephanie Oestreich
Managing Director
Myeloma Investment Fund

The panel will highlight strategies that are shaping a more inclusive and outcomes-focused future for healthcare through impact-driven investing.

Register today to join this discussion and connect with investors, entrepreneurs, and innovators at RESI Boston.

Tags: , , , , ,

Hot Investor Mandate: Cross-Border VC Firm Invests $10-20M in Early-Stage Therapeutics and Later-Stage Medical Devices in US and China 

19 Aug

A Beijing-based venture capital investor with offices across China and Hong Kong manages $8 billion USD in assets and is currently overseeing multiple funds, including RMB and USD funds. The firm invests across various sectors, with life sciences and healthcare being one of the major focus areas. The firm is capable of investing from early seed to pre-IPO. For early-stage investments, the sweet spot is from Seed to Series B, with average check sizes ranging from $10 million to $20 million USD. Follow-on investments are possible. The firm is open to both leading and co-investing and will consider board or observer seats on a case-by-case basis. In terms of geographic focus, the firm primarily targets opportunities based in the United States and China. 

The firm is most interested in biotech therapeutics or drugs and is open to various modalities such as cell therapies, antibodies, small molecules, and more. The firm is open to considering different indications, with preferences for solid tumors and autoimmune diseases. It prefers assets that are close to the IND phase or, at the very least, have obtained partial proof of concept. The firm is also open to considering medical instruments but typically focuses on companies at a later stage, generating revenue or profits. 

The firm does not have specific requirements for management teams but prefers teams with strong backgrounds and successful track records. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: USA-Based Seed Fund Invests in Software-Enabled Health Technologies, With Expanding Interests in Traditional Life Science Companies 

19 Aug

A US-based advisory group also manages a seed fund making investments into healthcare companies. Traditionally, the firm has strong expertise in enterprise software and is most interested in healthcare companies that have a software component (such as EHR/EMR integration), monitoring technologies, and early-stage detection devices and diagnostics. The firm is also starting to explore opportunities in traditional biotech investments and drug discovery-enabling tools. The firm considers global opportunities. 

The firm is currently exploring opportunities in traditional life sciences (therapeutics, diagnostics) as well as software or technology-enabled healthcare companies. While the firm is opportunistic regarding specific technologies and disease areas, the firm generally does not invest in companies that require FDA regulatory approval. 

The firm does not have specific company or management team requirements and has no preference on leading or co-investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Cross-Border Investment Firm Seeks Therapeutics and Medical Technologies, Investing from Seed to Pre-IPO

19 Aug

The firm is an investment firm based in Shanghai, China. The firm manages 30 billion RMB and invests in fund of funds as well as direct equity investments. The firm invests across multiple sectors, with life science and healthcare being one of its primary focuses. The sweet spot starts from pre-A rounds, and the firm can invest anywhere up to pre-IPO stages. While the firm primarily focuses on opportunities in China, it is open to global opportunities, particularly those interested in soft-landing in China/Shanghai or with a China angle. The firm is open to both leading investments and co-investing. 

Within life science and healthcare, the firm is most interested in biotech therapeutics and medical technologies. For therapeutics, the firm is open to exploring various modalities (excluding mRNA) and indications such as CNS and oncology. For medical devices, the firm seeks innovative technologies, including invasive technologies, imaging devices, and brain-computer interfaces, rather than non-innovative solutions such as consumables. 

The firm does not have specific requirements for a company’s founding team but prefers companies interested in coming to Shanghai/China. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Multi-Stage Generalist Seed Fund Invests Globally in Value-Based Life Sciences and Healthcare Companies

19 Aug

A multi-stage generalist venture capital investor can write flexible check sizes typically up to $300,000 for early-stage opportunities and can participate in follow-on investments. The firm is open to global companies. 

The firm has invested in digital health, techbio, value-based healthcare, and life sciences. The firm is disease-agnostic. Notable investments in healthcare have included digital health platforms, pharmacy solutions, clinical trial innovation, and biotech companies. 

The firm does not have specific company or management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Longevity Global Shapes the Longevity Track at RESI Boston

19 Aug

By Justin Taylor, Vice President of Communications, Longevity Global (Special Guest Contributor)

Innovation and Investment to Beat Aging and Age-Related Disease

Longevity Global is coming to RESI Boston on Wednesday, September 17, with a full day of programming dedicated to innovation and investment in the longevity space. This curated track will highlight cutting-edge science, startup founders, and investors who are accelerating solutions for aging and age-related diseases.

The day begins with coffee, networking, and opening remarks, followed by a keynote from Eric Morgen, Co-founder of BioAge, setting the stage for thought-provoking discussions on advancing longevity research. Morning sessions feature presentations from leaders such as Raghav Seghal (Yale), Christin Glorioso, MD, PhD (CEO, NeuroAge and Longevity Global), and Spring Behrouz (Vincere Bio), who will share perspectives on mitochondrial aging and fundraising in the field.

A Pharma Chat with Suguna Rachakonda (VP, Insilico) and Jon McClain (Executive Director, Lilly) will provide an industry lens on where big pharma sees opportunities in longevity.

The afternoon program kicks off with a keynote from Sharon Rosenzweig-Lipson (CSO, Life Biosciences), followed by Umbereen S. Nehal, MD, MPH, MBA (Founder, HER Heard, MIT) on the importance of women’s health interventions in extending lifespan and healthspan. Additional sessions include Ethan Berg (Founder, Winthrop Estate) on the case for investing in longevity, alongside an Investor Panel featuring Sally Wang (Managing Partner, XPanse Ventures), Ruta Laukien (VP, US Capital; Managing Partner, GrayBella Capital), and Fiona Miller (Managing Partner, quadraScope).

The Innovation Panel, moderated by Tom Zuber (Managing Partner, Zuber Lawler), will showcase voices across legal, biotech, and clinical perspectives, with speakers Frank Gerratana (Partner, Calyx Law), Shane Hegarty (CSO, AXONIS), and Jay Luthar, MD (Founder, Lutanen Health).

The program culminates with the Longevity Global Pitch Competition (Series A), where startups will showcase their technologies to a panel of seasoned investors. Winners will be announced by Daniel Dacey and The Engine, which will also award the winning company a full year of lab space—an invaluable resource for advancing early-stage science.

The day closes with the RESI Cocktail Hour, featuring wine and hors d’oeuvres, offering attendees the chance to network and celebrate innovation.

By bringing Longevity Global to RESI, this track provides an unparalleled platform for entrepreneurs and investors focused on combating aging and age-related disease. From scientific insights to investment strategies, the agenda is designed to drive meaningful dialogue and new connections in this rapidly advancing field.

Join us at RESI Boston to connect with the innovators and investors defining the future of longevity. Learn more

Tags: , , , , , , ,

← Older Entries
Newer Entries →